Sherbrooke Park Advisers LLC Sells 95,210 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO)

Sherbrooke Park Advisers LLC lessened its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 73.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,640 shares of the company’s stock after selling 95,210 shares during the period. Sherbrooke Park Advisers LLC’s holdings in Sutro Biopharma were worth $62,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. ProShare Advisors LLC grew its holdings in Sutro Biopharma by 74.3% in the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company’s stock worth $50,000 after purchasing an additional 11,494 shares during the period. Parkman Healthcare Partners LLC grew its holdings in Sutro Biopharma by 0.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,727,925 shares of the company’s stock worth $3,179,000 after purchasing an additional 11,793 shares during the period. Nuveen Asset Management LLC grew its holdings in Sutro Biopharma by 10.3% in the fourth quarter. Nuveen Asset Management LLC now owns 1,323,777 shares of the company’s stock worth $2,436,000 after purchasing an additional 124,154 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Sutro Biopharma by 4.6% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 859,373 shares of the company’s stock worth $1,581,000 after purchasing an additional 37,627 shares during the period. Finally, DAFNA Capital Management LLC grew its holdings in Sutro Biopharma by 32.6% in the fourth quarter. DAFNA Capital Management LLC now owns 437,079 shares of the company’s stock worth $804,000 after purchasing an additional 107,500 shares during the period. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

STRO opened at $0.84 on Thursday. The company’s 50-day moving average is $0.78 and its 200 day moving average is $1.70. Sutro Biopharma, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $5.17. The firm has a market capitalization of $70.80 million, a P/E ratio of -0.52 and a beta of 1.77.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.28). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The firm had revenue of $17.40 million for the quarter, compared to the consensus estimate of $11.61 million. On average, equities research analysts expect that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on STRO shares. Citizens Jmp cut shares of Sutro Biopharma from an “outperform” rating to a “market perform” rating in a report on Friday, March 14th. Bank of America reduced their price target on shares of Sutro Biopharma from $1.00 to $0.80 and set an “underperform” rating for the company in a report on Monday. HC Wainwright reiterated a “neutral” rating and set a $2.00 price objective on shares of Sutro Biopharma in a report on Tuesday, April 29th. Piper Sandler set a $2.00 price objective on shares of Sutro Biopharma in a report on Friday, March 14th. Finally, Wedbush cut shares of Sutro Biopharma from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $8.00 to $2.00 in a report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Sutro Biopharma presently has a consensus rating of “Hold” and a consensus target price of $6.11.

Sutro Biopharma Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.